Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

we lowered the list prices of the JANUVIA family of products in the U.S. to more closely align them with net prices. The lower list price will reduce the rebate amount Merck pays to Medicaid and ...

Merck on Tuesday issued full-year 2025 revenue ... cut HIV infections by 96% in trial Merck's Type 2 diabetes treatment, Januvia, also saw sales fall to $487 million during the quarter, down ...

Merck issued guidance for 2025 that lags consensus ... Those were partially offset by lower sales of diabetic medicines Januvia and Janumet, and lower combined sales of the human papillomavirus ...

(Reuters) -Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year ...

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...